AI-based decision support for robotic vertigo diagnosis and treatment device

BPPV-type vertigo affects 4% of the population, and each year, 1.4% of people visit the emergency room (ER) due to BPPV attacks. Unfortunately, the misdiagnosis rate for BPPV in the ER is alarmingly high, ranging from 74% to 80%. As a result, patients visit the hospital an average of seven times, and finding an effective cure can take up to 70 months.

 To address this issue, we have designed and manufactured a fully automatic robotic diagnostic and treatment chair specifically for BPPV patients. Our device has shown a remarkable success rate of 96.7% in official clinical trials, with an average treatment time of just 20 minutes. So far, we have successfully treated over 1,000 patients using our device.

 As the first of its kind, the GMDN agency issued a new code for our device in July 2023. It was also selected in the USA among the "Top 10 ENT Solution Providers 2024," alongside industry giants like Olympus, Ackermann, and Philips. Our technology is CE-certified, ensuring its quality and safety.

 Currently, we are integrating an AI-based decision support module to simplify the physician's task, as the decision-making process can be overly complex. Our ultimate goal is to place this device in ERs so that patients can receive treatment as soon as they enter the room.